Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564471 · ClinicalTrials.gov registry record · Phase 4
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
A Phase 4 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT02564471 is a Phase 4 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 103 participants.
The verdict
NCT02564471, a Phase 4 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
Interventions
- DRUG Doxycycline
- DRUG Chloroquine
- BIOLOGICAL Rabies Vaccine
- DRUG Atovaquone and Proguanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2019-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564471
The ClinicalTrials.gov registry entry for NCT02564471 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Doxycycline is the first listed.
NCT02564471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564471 about?
NCT02564471 is a clinical study titled "Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.". This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presenc...
What is the current status of trial NCT02564471?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2016-11-11. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02564471?
The interventions under investigation include: Doxycycline (DRUG), Chloroquine (DRUG), Rabies Vaccine (BIOLOGICAL), Atovaquone and Proguanil (DRUG).
Who is sponsoring clinical trial NCT02564471?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.